Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: rabeprazole sodium Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of RO7890597 in Healthy Adult Volunteers

NCT07797478
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RO7890597, Placebo, Rabeprazole, Itraconazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

NCT04488016
View directory record Official record
Conditions
Bioavailability, B-cell Lymphoid Cancer
Interventions
Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1, Treatment D- Part 1, Treatment A-Part 2, Treatment B - Part 2, Treatment C - Part 2, Treatment D - Part 2
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 4 Interventional

Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD

NCT00304421
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
rabeprazole, pantoprazole
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2007 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Results available

E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

NCT00236184
View directory record Official record
Conditions
Heartburn
Interventions
rabeprazole sodium, Placebo
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
19 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2010 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib

NCT01772290
View directory record Official record
Conditions
Healthy Volunteer
Interventions
fluconazole, itraconazole, rabeprazole, vismodegib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fruquintinib Food Effect and Proton Pump Inhibitor Study

NCT04645940
View directory record Official record
Conditions
Drug Interaction, Food-drug Interaction
Interventions
fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole, fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 4 Interventional Results available

Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors

NCT03094416
View directory record Official record
Conditions
Hypothyroidism;Postablative
Interventions
levothyroxine sodium capsule, Proton pump inhibitor (PPI), Levothyroxine Sodium (LT4) Tablets
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
La Jolla, California • Ventura, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

NCT02655614
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Tablets 20 mg

NCT00649194
View directory record Official record
Conditions
Healthy
Interventions
Rabeprazole Sodium Delayed-Release Tablets 20 mg, Aciphex® Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers

NCT04435483
View directory record Official record
Conditions
Pharmacokinetics, Bioavailability
Interventions
Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

NCT00839306
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole ER, Ranitidine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Moline, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Surufatinib DDI With a PPI and a CYP3A Inducer

NCT04510649
View directory record Official record
Conditions
Healthy
Interventions
Part A, Part B
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 2Phase 3 Interventional

Trial of Electrosurgical Incision Versus Bougie Dilation of Symptomatic Lower Esophageal (Schatzki's) Rings

NCT00204750
View directory record Official record
Conditions
Lower Esophageal Ring, Dysphagia
Interventions
Bougie Dilation, Needle-knife incision
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 3, 2008 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Gastric pH on the Pharmacokinetics of Dasatinib

NCT01398046
View directory record Official record
Conditions
Healthy
Interventions
Dasatinib, Dasatinib plus Rabeprazole, Dasatinib plus Rabeprazole AND Betaine Hydrochloride
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 59 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

NCT05446142
View directory record Official record
Conditions
Healthy
Interventions
Encorafenib capsule formulation (CAP), Encorafenib first formulation, Encorafenib second formulation, Rabeprazole tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers

NCT01101646
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
rabeprazole sodium
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

NCT04489797
View directory record Official record
Conditions
Infectious Disease
Interventions
Acalabrutinib, Rabeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 2 Interventional

Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00222170
View directory record Official record
Conditions
Esophageal Reflux
Interventions
Rabeprazole
Drug
Lead sponsor
University of Kansas
Other
Eligibility
19 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 7, 2009 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers

NCT00999128
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GDC-0941, rabeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Results available

Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

NCT00911534
View directory record Official record
Conditions
Symptomatic Gastroesophageal Reflux Disease (sGERD)
Interventions
rabeprazole sodium, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
98
States / cities
Athens, Alabama • Huntsville, Alabama • Tucson, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects

NCT04211545
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Rabeprazole, CC-92480
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT02637557
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
IW-3718, Matching Placebo, PPI
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
62
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 28, 2026, 6:23 PM EDT
Completed No phase listed Observational

A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms

NCT01286194
View directory record Official record
Conditions
Frequent Heartburn
Interventions
Rabeprazole sodium
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
33
States / cities
Scottsdale, Arizona • Griffin, Georgia • Lawrenceville, Georgia + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2011 · Synced Sep 28, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

NCT00992589
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
1 Month to 11 Months
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Columbiana, Alabama • Dothan, Alabama + 40 more
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Sep 28, 2026, 6:23 PM EDT